Search

Displaying results 1801 - 1810 of 8517 in total
  1. Drug

    Iodipamide

    go.drugbank.com/drugs/DB04711
    ApprovedWithdrawn

    Iodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.

    Synonyms: 3,3'-(adipoyldiimino)bis(2,4,6-triiodobenzoic acid)
  2. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    [L11022] Remestemcel-L was later approved by the FDA on December 18, 2024. … It was approved for use in Canada in May 2012 as Prochymal for the management of refractory acute Graft versus Host Disease (aGvHD) in children who are unresponsive to systemic steroid therapies, with

  3. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    [L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292] … [L15302] Its relative ubiquity across different stages of B-cell development, including pre-B and mature B-lymphocytes,[L15292] as well as its presence in several B-cell malignancies (e.g. chronic lymphocytic

  4. Drug

    Alirocumab

    go.drugbank.com/drugs/DB09302
    ApprovedInvestigational

    From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. … Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of

  5. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral … A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic

  6. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA...

  7. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    [L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g.

  8. Drug

    Liothyronine

    go.drugbank.com/drugs/DB00279
    ApprovedInvestigationalVet approved

    [T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]

  9. Drug

    Collagenase clostridium histolyticum

    go.drugbank.com/drugs/DB00048
    ApprovedInvestigational

    [L14872] Also known as Qwo, this injection is the first approved injectable treatment for cellulite and was developed by Endo International.[L14892] … [L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women.

  10. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    as major side effects. … Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as